Literature DB >> 31646556

A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers.

Y Wang1, L Lei, Y-G Chi, L-B Liu, B-P Yang.   

Abstract

OBJECTIVE: Ovarian cancer is one of the most common causes of cancer-related deaths in women. Many studies show that dysregulated gene expression plays a key role in tumorigenesis and development. Therefore, a comprehensive understanding of ovarian serous cystadenocarcinoma survival prognosis is needed. PATIENTS AND METHODS: A large number of high-dimensional RNA-sequencing files and clinical datasets collected from the Genomic Data Commons Data Portal were utilized to identify novel potential biomarkers for determining the prognosis of patients with ovarian serous cystadenocarcinoma (OVSC). We adopted a new strategy to identify these biomarkers by integrating co-expression network analysis and the Kaplan-Meier estimation with a non-parametric bootstrapping procedure.
RESULTS: Functional enrichment analysis of gene modules of interest revealed several dysregulated genes in OVSC, suggesting a close relationship between hormones and angiogenesis. In combination with this comprehensive approach, 14 genes, including ABCA10, DCX, LRRC30, ALX4, DKK4, SGCZ, ANKS4B, FHL5, SPRR2F, CHRNG, GABRR1, STMN2, CRHBP, and GSTM5, were shown to serve as candidate biomarkers for predicting the prognosis of patients with OVSC.
CONCLUSIONS: The current study identified several valuable prognostic biomarkers and several potential therapeutic targets for treating OVSC.

Entities:  

Year:  2019        PMID: 31646556     DOI: 10.26355/eurrev_201910_19136

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.

Authors:  Helen S Mueller; Colin E Fowler; Simona Dalin; Enrico Moiso; Tee Udomlumleart; Salil Garg; Michael T Hemann; Jacqueline A Lees
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

2.  Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.

Authors:  Xuewei Hao; Jun Zhang; Guoyou Chen; Weiwei Cao; Hongyang Chen; Shuo Chen
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

3.  A 4-gene signature predicts prognosis of uterine serous carcinoma.

Authors:  Hui Chen; Lingjun Li; Ping Qin; Hanzhen Xiong; Ruichao Chen; Minfen Zhang; Qingping Jiang
Journal:  BMC Cancer       Date:  2021-02-12       Impact factor: 4.430

4.  Loss of retinoic acid receptor-related receptor alpha (Rorα) promotes the progression of UV-induced cSCC.

Authors:  Guolong Zhang; Guorong Yan; Zhiliang Fu; Yuhao Wu; Fei Wu; Zhe Zheng; Shan Fang; Ying Gao; Xunxia Bao; Yeqiang Liu; Xiuli Wang; Sibo Zhu
Journal:  Cell Death Dis       Date:  2021-03-04       Impact factor: 8.469

5.  Development of a Gene Risk Signature for Patients of Pancreatic Cancer.

Authors:  Tao Liu; Long Chen; Guili Gao; Xing Liang; Junfeng Peng; Minghui Zheng; Judong Li; Yongqiang Ye; Chenghao Shao
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

6.  CircRNA_0084927 promotes colorectal cancer progression by regulating miRNA-20b-3p/glutathione S-transferase mu 5 axis.

Authors:  Feng Liu; Xiao-Li Xiao; Yu-Jing Liu; Ruo-Hui Xu; Wen-Jun Zhou; Han-Chen Xu; Ai-Guang Zhao; Yang-Xian Xu; Yan-Qi Dang; Guang Ji
Journal:  World J Gastroenterol       Date:  2021-09-28       Impact factor: 5.742

7.  Genome-wide association study of serum tumor markers in Southern Chinese Han population.

Authors:  Xiukuan Li; Fenghua Bai; Xingwei Wei; Tianbo Jin; Chen Li; Yutian Zhang; Mei Lin; Xiaoli Zhou; Yufei Xie; Chanyi He; Qi Lin; Ping He; Shuyuan Chu; Yipeng Ding
Journal:  BMC Cancer       Date:  2022-02-10       Impact factor: 4.430

8.  Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer.

Authors:  Yeong-Chin Jou; Shou-Chieh Wang; Yuan-Chang Dia; Shou-Tsung Wang; Min-Hua Yu; Hsin-Yi Yang; Lei-Chin Chen; Cheng-Huang Shen; Yi-Wen Liu
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.